References
- Haddad A, Tyan P, Radwan A, et al. β-Thalassemia intermedia: A bird’s-eye view. Turk J Hematol. 2014;31(1):5–16
- Taher AT, Musallam KM, Karimi M, Cappellini MD. Contemporary approaches to treatment of β-thalassemia intermedia. Blood Rev. 2012;26(Suppl 1):S24–S27
- Karimi M, Yarmohammadi H, Farjadian S, et al. β-Thalassemia intermedia from southern Iran: IVS-II-1 (G→A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002;26(2):147–154
- Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β-thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523
- Taher AT, Musallam KM, Cappellini MD. Thalassemia intermedia: An update. Mediter J Hematol Infect Dis. 2009;1(1):e2009004. doi: 10.4084/MJHID.2009.004
- Kimura EM, Grignoli CRE, Pinheiro VRP, et al. Thalassemia intermedia as a result of heterozygosis for β0-thalassemia and αααanti-3.7/αα genotype in a Brazilian patient. Braz J Med Biol Res. 2003;36(6):699–701
- Galanello R, Cao A. Relationship between genotype and phenotype: Thalassemia intermedia. Ann N Y Acad Sci. 1998;850:325–333
- Thein SL. Dominant β thalassaemia: Molecular basis and pathophysiology. Br J Haematol. 1992;80(3):273–277
- Thein SL. Genetic modifiers of β-thalassemia. Haematologica. 2005;90(5):649–660